YOLFTbeta
HeXun Biosciences Co., Ltd.

HeXun Biosciences Co., Ltd.

6986 · TWO · Healthcare / Biotechnology

40.00TWD+2.50 (+6.67%)

Price History

Full chart

Market Stats

Previous Close37.50
Open37.50
Day Range37.10 – 41.20
52-Week Range39.40 – 71.28
Volume94.00K
Market Cap2.29B
P/E (TTM)18.64
Forward P/E0.00
EPS2.36
Dividend Yield0.44%
Beta0.09
50-Day Avg42.93
200-Day Avg54.20

About

HeXun Biosciences Co., Ltd. engages in the research and development of stem cell drug development and cardiovascular disease treatments in Taiwan. It provides contract manufacturing; commissioned inspection; aseptic filling; and consulting services. The company was founded in 2019 and is based in Taoyuan City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Ji-Hong Huang
  • Employees53
  • HeadquartersNo. 1490, Chunri Road, Taoyuan City, Taiwan, 33022, Taiwan
  • Websitehttps://www.hexunbio.com

Leadership

  • Mr. Ji-Hong HuangPresident & Chairman
  • Yushen LanAccounting & Finance Director
  • Arvin ChenVice President of Technology Management
  • Fred ChengDirector of Administration

Financials

Income Statement

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue049.47M130.57M286.42M293.23M
Growth (%)--+163.95%+119.36%+2.38%
Cost of Revenue04.86M16.84M25.75M26.95M
Gross Profit044.61M113.73M260.67M266.27M
Gross Margin-90.18%87.10%91.01%90.81%
Operating Expense50.66M48.16M86.36M104.94M148.27M
Operating Income-50.66M-3.55M27.37M155.73M118.00M
Operating Margin--7.17%20.96%54.37%40.24%
EBITDA-29.51M11.17M55.64M186.07M155.98M
EBITDA Margin-22.58%42.62%64.97%53.20%
Net Income-42.99M-5.19M33.49M147.22M111.91M
Net Income Margin--10.49%25.65%51.40%38.16%
R&D44.71M39.36M53.22M65.37M99.18M
R&D as % of Total Revenue-79.57%40.76%22.82%33.82%
Interest Expense1.57M1.64M1.85M1.18M1.11M
Interest Expense % of Total Revenue-3.31%1.42%0.41%0.38%

Balance Sheet

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets266.24M294.62M404.15M571.43M706.92M837.07M
Total Liabilities86.50M79.86M89.28M98.07M86.34M95.47M
Total Equity179.74M214.75M314.87M473.36M620.58M741.60M
Cash71.69M85.03M119.74M257.67M200.99M208.20M
Total Debt80.87M74.10M69.42M70.06M35.02M-
Net Debt9.18M-10.93M-50.32M-187.61M-165.97M-

Cash Flow

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-35.50M11.23M43.09M120.92M163.89M
Investing Cash Flow-26.95M-79.05M-25.28M-137.29M-
Financing Cash Flow75.79M102.54M120.12M-40.30M-
Capital Expenditure01.23M22.81M37.29M28.86M
Free Cash Flow-35.50M10.00M20.28M83.63M135.04M
FCF to OCF100.00%89.07%47.06%69.16%82.39%

Key Statistics & Ratios

Market Cap2.29B
Enterprise Value1.58B
Trailing P/E18.64
Forward P/E0.00
Price / Sales7.44
Price / Book2.22
EPS2.36
Book Value20.50
Revenue (TTM)308.21M
Gross Profit (TTM)280.37M
EBITDA155.92M
Profit Margin37.74%
Operating Margin54.48%
Return on Equity13.26%
Return on Assets8.31%
Shares Outstanding52.13M
Shares Float31.40M
Beta0.09
Dividend Yield0.44%
Dividend Rate0.19
Payout Ratio0.00%

Dividends

20261×
0.19Aug 18, 2026